Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaSurgics, a biotechnology company, has received approval from the Swedish medical product agency to proceed to Phase I clinical documentation with the novel candidate drug, PXL01, indicated for post-surgical adhesion prevention. The clinical program will be initiated in March 2009.
Subscribe to our email newsletter
PharmaSurgics patented drug candidate PXL01, has demonstrated an excellent effect and safety profile in preclinical studies and the first clinical trial on patients are planned to start in the end of 2009.
PharmaSurgics goal is to be first to market with a pharmacological product for the prevention of post-surgical adhesions.